FDA Grants Fast Track Status to TRE-515 for Lung Cancer

The FDA has granted Fast Track designation to TRE-515 for its use with KRAS G12C inhibitors in previously treated KRAS G12C mutation-positive non-small cell lung cancer (NSCLC) patients. This marks the second Fast Track designation for TRE-515, aiming to expedite development and review for serious conditions with unmet medical needs. The designation could accelerate the availability of a new treatment option for this specific lung cancer population.